Publication: Cornea As a Model for Testing CTGF-Based Antiscarring Drugs
Open/View Files
Date
2017
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sriram, Sriniwas, Jennifer A. Tran, and James D. Zieske. 2017. “Cornea As a Model for Testing CTGF-Based Antiscarring Drugs.” Bone and tissue regeneration insights 7 (1): 10.4137/BTRI.S19954.
Research Data
Abstract
Scarring remains a serious complication of the wound healing process that can lead to the formation of excessive fibrous connective tissue in an organ or tissue leading to pain and loss of function. This process is mainly regulated by Transforming growth factor β1 (TGF-β1), which binds to receptors and induces its downstream mediator, Connective tissue growth factor (CTGF). The number of drugs targeting CTGF for treating scars has been on the rise in the past few years. The purpose of this article is to suggest the possibility of using cornea as a model for testing anti-CTGF therapies for scarring.
Description
Other Available Sources
Keywords
CTGF, corneal scar, skin scarring, scarring treatments
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service